Jubilant Pharmova Ltd News
CDMO shares under pressure; Neuland, Laurus, Syngene tank up to 12%
Thus far in the calendar year 2024 (CY24), the market price of Neuland Laboratories has zoomed 216%, Piramal Pharma (88%), Divi's Labs (53%) and Jubilant Pharmova (52%)
 "CDMO shares under pressure; Neuland, Laurus, Syngene tank up to 12%")
Jhunjhunwala Portfolio: This pharma stock has zoomed over 100% in 6 months
Shares of Jubilant Pharmova surged 12 per cent on the BSE in Friday's intra-day trade to hit a new high of Rs 1,169.55, in an otherwise subdued market.
 "Jhunjhunwala Portfolio: This pharma stock has zoomed over 100% in 6 months")
Jubilant Pharmova hits all time high on receiving 'VAI' tag for US facility
Jubilant Pharmova share price rose as much as 4.2 per cent, touching its all time high at Rs 1060.15 per share on the BSE in early hours of Wednesday's intraday deals
 "Jubilant Pharmova hits all time high on receiving 'VAI' tag for US facility")
Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%
Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.
 "Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%")
Jubilant Pharmova Q1 results: Net profit rises multi-fold to Rs 481.8 cr
Jubilant Pharmova Ltd on Friday reported a multi-fold jump in consolidated net profit to Rs 481.8 crore boosted by gain on sale on investment in associate firm SOFIE Biosciences Inc USA. The company had posted a consolidated net profit of Rs 6 crore a year earlier, Jubilant Pharmova said in a regulatory filing. Consolidated total revenue from operations stood at Rs 1,731.7 crore as against Rs 1,586.9 crore in the year-ago period, it added. The exceptional items in the first quarter of the current fiscal include net income of Rs 669.2 crore following sale of investment in SOFIE, expenses of Rs 91.6 crore accrued due to closure of manufacturing operations of solid dosage formulation facility at Salisbury, Maryland, USA; Rs 95.3 crore provision for slow moving inventory in respect of solid dosage formulation business and litigation cost of Rs 50 crore among others. During the quarter, Jubilant Pharmova said its radiopharmaceuticals segment revenue grew 28 per cent year-on-year to Rs 2
 "Jubilant Pharmova Q1 results: Net profit rises multi-fold to Rs 481.8 cr")
